The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials

Dongmei Wang1, Jieying Liu1,2†, Ling Zhong1, Shunhua Li1, Liyuan Zhou1, Qian Zhang1, Ming Li1 and Xinhua Xiao1*†

1Department of Endocrinology, NHC Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China, 2Department of Medical Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Aims: Inflammatory biomarkers may play vital roles in the pathophysiology of diabetes and diabetic cardiorenal complications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have a potential cardiovascular and renal protective effect in type 2 diabetes. The aim of this meta-analysis was to quantify the effects of SGLT2 inhibitors on biomarkers of inflammation in randomized controlled trials (RCTs).

Methods: PubMed, Cochrane Library, EMBASE, and Web of Science were searched for eligible RCTs of adults with type 2 diabetes (T2D) with no time limit (updated to 12 October 2022). The biomarkers selected included C-reactive protein (CRP), interleukin-6, tumor necrosis factor-alpha, leptin, adiponectin, ferritin, plasminogen activator (PAI)-1, and vascular cell adhesion molecule-1. Data were analyzed using a random-effect model in Review Manager 5.4.

Results: Thirty-four studies with 6,261 patients (68.6% male) were eligible for this meta-analysis. The mean age of the participants was 62.57(±11.13) years old, and the median treatment duration length with follow-up was 24 weeks. Generally, the included trials were of good methodological quality. The meta-analysis revealed that ferritin levels were significantly reduced in SGLT2 inhibitor treatment groups versus placebo or standard diabetes therapies (SMD: −1.21; 95% CI: −1.91, −0.52, p < 0.001). The effects of CRP (SMD: 0.25; 95% CI: −0.47, −0.03, p = 0.02) and leptin (SMD: −0.22; 95% CI: −0.43, −0.01, p = 0.04) were reduced, and the effects of adiponectin were improved (SMD: 0.28; 95% CI: 0.15, 0.41, p < 0.001) in placebo-controlled studies. PAI-1 levels were significantly reduced in studies controlled for diabetes therapies (SMD: −0.38; 95% CI: −0.61, −0.15, p = 0.001).

Conclusion: This analysis provides strong evidence supporting anti-inflammatory effects of SGLT2 inhibitors in T2D subjects. The mechanisms...
and possible targets for the inflammation reducing and cardiorenal protective properties of SGLT2 inhibitors remain to be explored.

KEYWORDS
SGLT2 inhibitor, inflammation, diabetes, meta-analysis, randomized controlled trial

Introduction

There has been a dramatic increase in the prevalence of type 2 diabetes (T2D) in recent years that has reached epidemic proportions (Zheng et al., 2018). Diabetic hyperglycemia often causes both macrovascular and microvascular pathological changes, resulting in increased cardiovascular disease (CVD), diabetic nephropathy risks, and reduced survival rates (Braunwald, 2019). Chronic inflammation in T2D is widely believed to be closely linked to the onset and progression of cardiorenal dysfunction (Luc et al., 2019; Rohm et al., 2022). Hyperglycemia-related diabetic CVD and retinopathy have been reported to be accompanied by the activation of proinflammatory biomarkers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) (Qu et al., 2014; Feigerlová and Battaglia-Hsu, 2017; Khaloo et al., 2020). Two adipokines, adiponectin and leptin, are vital biomarkers of metabolic disease and CVD (Everson-Rose et al., 2021; Zhao et al., 2021). A high leptin/adiponectin ratio in patients with gestational diabetes mellitus was related to a higher CVD risk profile during follow-up in a prospective cohort study (Lekva et al., 2017). In addition, plasminogen activator inhibitor (PAI)-1 and vascular cell adhesion molecule (VCAM)-1 have been reported to be significantly increased in diabetic vascular disorders (Altalhi et al., 2021; Bilen et al., 2021). Therefore, hypoglycemic intervention may exert its role in the prevention of diabetic cardiorenal complications by inhibiting inflammation (Luc et al., 2019; Altalhi et al., 2021).

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been approved for T2D treatment since 2012 (Cahn et al., 2021). Several large clinical trials, such as EMPORER-Reduced, CANVAS-R, and DAPA-HF, have provided significant clinical evidence of cardiac and renal protection in patients with or without diabetes (Neal et al., 2017; Zannad et al., 2020; Packer et al., 2021). Experimental in vitro and in vivo studies have shown anti-inflammatory properties of SGLT2 inhibitors as a possible beneficial mechanism of SGLT2 inhibitors (Winiańska et al., 2021; Marfella et al., 2022; Scisciola et al., 2022). Bray et al. summarized the evidence of the effects of SGLT2 inhibitors on four inflammatory biomarkers (CRP, IL-6, TNF-α, and adiponectin) in a systematic review including literatures searched up to the end of December 2019. However, the impacts of SGLT2 inhibitors on inflammatory biomarkers were inconsistent in the reviewed literature (Bray et al., 2020). In addition to randomized controlled trials (RCTs), they also included observational studies (Bray et al., 2020). In the past three years, many new RCTs studies have been published on the effects of SGLT-2 inhibitors on biomarkers of inflammation (Docherty et al., 2022; Omar et al., 2022; Takahashi et al., 2022). In addition to the abovementioned biomarkers, ferritin, a specific inflammatory indicator, has been found to be significantly reduced in SGLT2 inhibitor-treated participants (Kinoshita et al., 2020; Alshnbari and Idris, 2022; Takahashi et al., 2022). Therefore, in this meta-analysis we mainly focused on RCTs and included more inflammatory biomarkers to assess the comprehensive effects of SGLT2 inhibitors on biomarkers of inflammation.

Materials and methods

Literature search strategy

Four electronic databases (PubMed, Cochrane Library, EMBASE, and Web of Science) were searched for eligible studies without any time limit (updated to 12 October 2022). The keywords used in the search were (sodium-glucose cotransporter 2 inhibitor* OR SGLT-2 inhibitor* OR SGLT 2 inhibitor* OR SGLT2 inhibitor* OR glitazin* OR canagliflozin OR dapagliflozin OR empagliflozin OR ertugliflozin OR ipragliflozin OR licogli flozin OR remogliflozin OR sorgli flozin) AND (inflammation OR C-reactive protein OR interleukin-6 OR tumor necrosis factor-alpha OR leptin OR adiponectin OR plasminogen activator inhibitor-1 and vascular cell adhesion molecule-1 OR ferritin) AND randomized controlled trials. The literature search was conducted in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines (Supplementary Table S1). A detailed list of the search terms is given in Supplementary Table S2.

Inclusion criteria and exclusion criteria

We included all peer-reviewed, published English-language papers of individual RCTs of any SGLT2 inhibitor in adults with T2D. RCTs comparing SGLT2 inhibitors to placebo or other hypoglycemic agents were included without restriction of diabetes duration or length of follow-up. Observational studies, duplicate reports, and articles not reporting outcomes of interest or without original data in human participants were excluded. Studies of prediabetics, pregnant women, type I diabetics, or participants receiving SGLT2 inhibitors with fixed-dose combinations or comparisons of different SGLT2 inhibitors were also excluded.
Outcomes of biomarkers of interest

Our primary outcomes were the changes in the levels of inflammatory biomarkers of interest after treatment with any SGLT2 inhibitor compared to placebo or active control. The biomarkers selected were those that are widely accepted or relevant to clinical therapy (Bray et al., 2020; Bray et al., 2021), including CRP, TNF-α, IL-6, leptin, adiponectin, PAI-1, VCAM-1, and ferritin.

Data extraction and quality assessment

Two researchers (DMW and JYL) searched the literature independently and extracted data independently based on a standardized data extraction process. The detailed data extraction items included: first author, publication year, population, number of participants, treatment duration, study arms (placebo or diabetes medications), sample characteristics, effect sizes, and 95% CIs. The quality of the identified RCTs was assessed using the Review Manager 5.4 (Cochrane Collaboration, Oxford, United Kingdom) risk of bias tool, which has four sections: recruitment bias, baseline imbalance, loss of clusters, and incorrect analysis. The possible answers were low risk of bias, high or unclear according to the Cochrane Handbook (Higgins et al., 2011). The assessment of publication bias was conducted using a funnel plot. Any disagreements that appeared during the data extraction and quality assessment were resolved by consensus or by a third reviewer as needed (XHX).

Statistical analysis

In the primary analysis we compared biomarkers of inflammation in patients treated with SGLT2 inhibitors with those receiving placebo or other diabetes medications. The differences in means during the follow-up periods between the treatment and placebo groups was calculated using standardized mean differences (SMDs) with 95% confidence intervals (CIs). Data were analyzed using a random-effect model. If multiple doses or multiple control groups were reported in the same study, a weighted average was taken and combined (Bray et al., 2021). If the mean and SD were not presented, SD was determined from the standard error of the mean, or values were estimated from the sample size, median, range, and/or interquartile range using methodology from the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0). Heterogeneity across studies was assessed by the I² statistic.
TABLE 1 Main characteristics of patients included in the meta-analysis.

| Trials                        | No. of participants | Treatment duration | Population | Study arms                                                                 | Age (year) | No. (%) of male | BMI (kg/m²) | HbA1c (%) | Diabetes duration (year) |
|-------------------------------|---------------------|--------------------|------------|-----------------------------------------------------------------------------|------------|-----------------|-------------|-----------|------------------------|
| Docherty et al., 2022         | 2423                | 12 months          | T2D, multiple countries                                                Dapagliflozin 10 mg/day; placebo | 67.2 ± 10.4 | (77.9)           | 28.5 ± 5.9 | -         | -                      |
| Ejiri et al., 2022            | 157                 | 12 weeks           | T2D with heart failure, Japan                                           Luseogliflozin 2.5 mg/day; voglibose | 71.8 ± 7.8 | 54 (68.4); 45 (57.7) | 25.4 ± 4.4; 25.1 ± 4.2 | 7.0 ± 0.7; 6.9 ± 0.8 | 72 (24–130)*; 72 (36–138)* |
| Takahashi et al., 2022        | 50                  | 72 weeks           | T2D with NAFLD, Japan                                                  Ipragliflozin 50 mg/day; antidiabetic drugs | 59.0 (46.8–64.3); 50.0 (48.0–68.8) | 15 (62.5); 14 (53.8) | 29.9 (27.2–32.3); 28.8 (25.7–32.9) | 6.5 | - |
| Omar et al., 2020             | 187                 | 12 weeks           | T2D with stable HFrEF, Denmark                                         Empagliflozin, placebo | 65 ± 10; 63 ± 12 | 78 (83); 81 (87) | 29 (26–32); 28 (26–33) | 40 (36–43)*; 39 (36–42)* | - |
| Hao et al., 2022              | 142                 | 12 weeks           | Newly-diagnosed T2D, China                                             Canagliflozin 100 mg/day; metformin | 57.3 ± 9.8; 56.0 ± 8.5 | 36 (52.2); 39 (53.4) | 26.4 ± 5.0; 26.3 ± 4.8 | 7.9 ± 0.4; 8.0 ± 0.4 | less than 6 months |
| Oldgren et al., 2021          | 49                  | 6 weeks            | T2D, Sweden and Finland                                               Dapagliflozin 10 mg/day; placebo | 63.5 ± 7.9; 65.4 ± 6.5 | 9 (37.5); 17 (68) | 30.2 ± 3.6; 30.1 ± 3.8 | 6.74 ± 0.58; 6.67 ± 0.65 | 5.3 |
| Thiele et al., 2021           | 42                  | 3 months           | T2D, Germany                                                          Empagliflozin 10 mg/day; placebo | 62.8 ± 5.4; 61.2 ± 7.9 | 16 (80); 18 (81.8) | 31.4 ± 5.3; 31.2 ± 4.0 | 7.8 ± 1.5; 7.9 ± 1.3 | 9 (4–14); 10 (9–16) |
| Kaku et al., 2014             | 235                 | 24 weeks           | T2D, Japan                                                            Tofogliflozin 10 mg/day; tofogliflozin 20 mg/day; tofogliflozin 40 mg/day; placebo | 57.0 ± 6.9; 56.6 ± 10.2; 56.8 ± 9.9 | 5 (27.8); 38 (66.7); 37 (66.1) | 29.6 ± 4.0; 28.8 ± 4.1; 26.0 ± 4.1 | 8.2 ± 0.8; 7.8 ± 0.6; 8.41 ± 0.78 | 4.5 (2–10); 5.5(2–5) |
| Sako et al., 2016              | 49                  | 12 weeks           | T2D, Japan                                                            Empagliflozin 10 mg/day; standard therapy | 58.6 ± 12.9; 58.6 ± 12.2 | 16 (51.6); 12 (66.7) | 27.2 ± 5.7; 28.4 ± 6.6 | 8.00 ± 0.86; 7.63 ± 0.55 | - |
| Kinoshita et al., 2020        | 98                  | 28 weeks           | T2D with NAFLD, Japan                                                Dapagliflozin 5 mg/day; pioglitazone; glimepiride | 58.7 ± 1.6; 59.0 ± 1.9 | 15 (46.9); 15 (45.5) | 29.5 ± 0.8; 28.7 ± 0.9 | 7.4 ± 0.2; 7.4 ± 0.2 | 6.6 ± 0.9; 6.4 ± 0.8 |
| Katakami et al., 2020         | 339                 | 104 weeks          | T2D, Japan                                                            Tofogliflozin 20 mg/day; Conventional treatment | 61.3 ± 9.3; 58.0 ± 2.3 | 99 (58.6); 15 (45.5) | 27.0 ± 5.8; 28.4 ± 0.7 | 7.4 ± 0.7; 7.6 ± 0.2 | 12.1 ± 8.4; 7.2 ± 1.0 |
| Kahl et al., 2020             | 84                  | 24 weeks           | T2D, Germany                                                          Empagliflozin 25 mg/day; placebo | 62.7 ± 7.0; 61.5 ± 10.0 | 29 (69); 29 (69) | 32.1 ± 4.6; 32.4 ± 4.2 | 6.8 ± 0.5; 6.7 ± 0.7 | 36 ± 27*; 40 ± 27* |
| Eickhoff et al., 2020         | 36                  | 12 weeks           | T2D with albuminuria, Denmark                                         Dapagliflozin 10 mg placebo | 64 ± 8; 32 ± 89 | 32.8 ± 5.7 | 8.9 ± 1.4 | 16.4 ± 4.7 | - |

(Continued on following page)
TABLE 1 (Continued) Main characteristics of patients included in the meta-analysis.

| Trials                        | No. of participants | Treatment duration | Population Study | Study arms | Age (year) | No. (%) of male | BMI (kg/m²) | HbA1c (%) | Diabetes duration (year) |
|-------------------------------|---------------------|--------------------|------------------|------------|------------|----------------|-------------|-----------|------------------------|
| Brown et al., 2020            | 66                  | 12 months T2D with LVH, UK | Dapagliflonzin 10 mg/day; Placebo | 64.25 ± 7.01, 32.30 ± 4.66; 61.75 ± 11.10; 60.18 ± 10.15 | 57.75 ± 11.10; 8.5 (5.25, 14.5); 10.0 (7.5, 15.0) |
| Phrommintikul et al., 2019    | 49                  | 24 weeks T2D, Thailand | Dapagliflonzin 10 mg/day; vildagliptin | 62.60 ± 8.27, 25.63 ± 3.00; 8.17 ± 1.41 | 63.88 ± 7.65, 8.25 ± 1.13 |
| Latva-Rasku et al., 2019      | 31                  | 8 weeks T2D, Finland | Dapagliflonzin 10 mg/day; placebo | 62 ± 7, 32.1 ± 3.9; 7.0 ± 0.6; 6.8 ± 0.5 | 60 ± 7, 28.3 ± 3.5, 7.70 ± 1.24 |
| Kobizaka et al., 2019         | 98                  | 24 weeks T2D, Japan | Ipragliflonzin 50 mg/day; metformin | 56.6 ± 11.9, 27.55 ± 4.24; 7.95 ± 0.73 | 55.7 ± 12.2, 28.83 ± 5.32, 8.12 ± 0.80 |
| Bosch et al., 2019            | 58                  | 6 weeks T2D, Germany | Empagliflonzin 25 mg/day; placebo | 62 ± 7, 29.5 ± 3.9; 6.69 ± 0.82 | 60 ± 7, 25.0 ± 3.1, 6.84 ± 0.85 |
| Aso et al., 2019              | 57                  | 24 weeks T2D with NAFLD, Japan | Dapagliflonzin 5 mg/day; standard treatment | 56.2 ± 11.5, 27.6 ± 4.7; 8.37 ± 1.48 | 57.1 ± 13.8, 28.3 ± 3.5, 7.70 ± 1.24 |
| Seino et al., 2018            | 233                 | 52 weeks T2D, Japan | Luseogliflozin 2.5 mg/day; placebo | 57.4 ± 10.3, 25.42 ± 3.53; 8.70 ± 0.83 | 57.1 ± 10.9, 25.15 ± 3.44, 8.84 ± 0.83 |
| Hattori, 2018                 | 102                 | 1 year T2D, Japan | Empagliflonzin 10 mg/day; placebo | 57.4 ± 12.3, 31.0 ± 4.8; 7.01 ± 1.1; 6.84 ± 0.85 | 58.1 ± 9.71, 7.4 ± 1.1, 6.84 ± 0.85 |
| Sato et al., 2018             | 40                  | 6 months T2D with CAD, Japan | Conventional therapy | 68 ± 4; 26.6 ± 4.6; 7.2 ± 0.6; 25.0 ± 3.1 | 66 ± 6, 7.4 ± 1.1, 6.84 ± 0.85 |
| Garvey et al., 2018           | 200                 | 52 weeks T2D, multiple countries | Canagliflonzin 300 mg/day glimepiride | 58.5 ± 9.0, 32.5 ± 4.7; 7.8 ± 0.9; 7.5 ± 6.0 | 57.5 ± 8.6, 31.7 ± 5.0, 7.7 ± 0.8, 6.8 ± 4.9 |
| Dekkers et al., 2018          | 31                  | 6 weeks T2D with albuminuria, the Netherlands | Dapagliflonzin 10 mg/day; placebo | 62 ± 8.1, 31 ± 5.4; 56 ± 8.5; 56 ± 8.5* | 61 ± 8.1, 7.4 ± 1.1, 6.84 ± 0.85 |
| Shigiyama et al., 2017        | 74                  | 16 weeks T2D, Japan | Dapagliflonzin 5 mg/day; metformin | 57.9 ± 8.3, 26.8 ± 4.6; 6.8 ± 0.5; 5.4 ± 4.4 | 59.4 ± 10.1, 26.3 ± 3.5, 6.9 ± 0.5, 6.3 ± 4.2 |
| Ito et al., 2017              | 66                  | 24 weeks T2D with NAFLD, Japan | Ipragliflonzin 50 mg/day; pioglitazone | 57.3 ± 12.1, 30.7 ± 5.0; 8.5 ± 1.5; 8.7 ± 5.8 | 59.1 ± 9.8, 29.9 ± 6.2, 8.3 ± 1.4, 9.5 ± 5.8 |
| Ishihara et al., 2016         | 255                 | 16 weeks T2D, Japan | Ipragliflonzin 50 mg/day; placebo | 58.7 ± 11.1, 26.1 ± 3.5; 8.67 ± 0.77; 151.1 ± 93.5; 171.4 ± 102.5 | 59.2 ± 9.3, 26.42 ± 3.81, 8.62 ± 0.86, 171.4 ± 102.5 |
| Kashiwagi et al., 2015a       | 151                 | 24 weeks T2D, Japan | Ipragliflonzin 50 mg/day; placebo | 56.2 ± 10.22, 27.11 ± 3.85; 8.24 ± 0.67; 76.0 ± 56.57; 92.5 ± 63.87 | 56.1 ± 11.91, 27.31 ± 4.31, 8.39 ± 0.64, 92.5 ± 63.87 |
| Kashiwagi et al., 2015b       | 129                 | 16 weeks T2D, Japan | Ipragliflonzin 50 mg/day; placebo | 60.6 ± 9.4, 25.3 ± 3.1; 8.40 ± 0.86; 90.4 ± 82.6; | 58.3 ± 10.5, 25.6 ± 3.9, 8.25 ± 0.68, 70.8 ± 61.1* |

(Continued on following page)
Results

Search results and description of the included studies

The PRISMA flow chart summarizes the search and study selection process (Figure 1). The electronic search yielded 1,772 unique records, of which 295 were reviewed in full text. In total, thirty-four RCTs, comprising 6,261 patients (68.64% male), were included in the final meta-analysis. Of the 34 trials from which data were used for this analysis, most of the studies were of a parallel design, except for two crossover designs. Except for three multinational trials (Garvey et al., 2018; Oldgren et al., 2021; Docherty et al., 2022), most trials were recruited from ten different countries: 17 from Japan (Kaku et al., 2014; Kashiwagi et al., 2015a; Kashiwagi et al., 2015b; Kashiwagi et al., 2015c; Ishihara et al., 2016; Ito et al., 2017; Shigiyama et al., 2017; Hattori, 2018; Sato et al., 2018; Seino et al., 2018; Aso et al., 2019; Koshizaka et al., 2019; Katakami et al., 2020; Kinoshita et al., 2020; Sakurai et al., 2020; Ejiri et al., 2022; Takahashi et al., 2022); three from Germany (Bosch et al., 2019; Kahl et al., 2020; Thiele et al., 2021); two from Denmark (Eickhoff et al., 2020; Omar et al., 2022); two from the United Kingdom (Bailey et al., 2012; Brown et al., 2020); two from Thailand (Phrommimitkul et al., 2019; Phrueksotsai et al., 2021); one from China (Hao et al., 2022); one from Austria (Antlinger et al., 2022); one from Brazil (Sposito et al., 2021); one from Finland (Latva-Rasku et al., 2019); and one from the Netherlands (Dekkers et al., 2018). The study characteristics are listed in Table 1. The median length of follow-up was 24 weeks. The mean participant age was 62.57(±11.13) years old, the mean body mass index was 28.23(±5.39) kg/m², the mean HbA1c (%) was 8.02(±4.64), and the mean diabetes duration was 8.27(±7.39) years.

### Table 1 (Continued) Main characteristics of patients included in the meta-analysis.

| Trials               | No. of participants | Treatment duration | Population | Study arms                          | Age (year) | No. (%) of male | BMI (kg/m²) | HbA1c (%) | Diabetes duration (year) |
|----------------------|---------------------|--------------------|------------|-------------------------------------|------------|-----------------|-------------|------------|--------------------------|
| Kashiwagi et al., 2013c | 240                 | 24 weeks           | T2D, Japan | Ipragliflozin 50 mg/day; placebo     | 59.6 ± 10.02 | 111 (67.3) | 25.81 ± 3.60 | 8.38 ± 0.64 | 123.8 ± 84.99          |
| Bailey et al., 2012   | 282                 | 24 weeks           | T2D, UK    | Dapagliflozin 1 mg/day; dapagliflozin 2.5 mg/day; dapagliflozin 5 mg/day; placebo | 53.7 ± 9.04 | 38 (52.8) | 32.53 ± 5.68 | 7.8 ± 0.98 | 16 ± 2.55            |

T2D, type 2 diabetes; NAFLD, non-alcoholic fatty liver disease; HFrEF, heart failure with reduced ejection fraction; CKD, chronic kidney disease; CVD, cardiovascular disease; LVH, left ventricular hypertrophy; BMI, body mass index.

*HbA1c (mmol/mol); #diabetes duration (months).

**Figure 2**
Summary of risk of bias using the Cochrane risk of bias tool.
Risk of bias and quality assessment

The methods for risk-of-bias and quality assessment are shown in Figure 2 and Supplementary Figure S1. Due to a lack of detailed methods, 31.4% of assessments across all domains were “unclear risk of bias”. Ten of the 34 studies were judged to have a “high risk of bias” for one domain. Two studies were assessed as having a “high risk of bias” for selection bias and performance bias. With the exception of ten open-label studies, 68.8% of studies reported double-blinding, but most did not describe the steps taken to ensure double-blinding. The majority of included studies were assessed as having a “low risk of bias” for at least four domains.

Meta-analysis results

CRP

The pooled effect size of 14 eligible trials (1794 subjects) demonstrated that there was no significant reduction in CRP concentrations (SMD: −0.01; 95% CI: −0.28, 0.26, \( p = 0.95 \)), with considerable heterogeneity.
between studies ($I^2 = 86\%, p < 0.001$; Figure 3).

Subgroup analyses were performed based on study arms and showed a significant CRP-lowering effect in placebo-controlled studies (SMD: $-0.25\%; 95\% CI: -0.47, -0.03$, $p = 0.02$) but not in diabetes medication-controlled studies (SMD: 0.24; 95% CI: -0.20, 0.68, $p = 0.29$). In addition, the source of heterogeneity seemed to be mainly from the diabetes medications-controlled subgroup.

**TNF-α**

A total of seven studies explored the effects of SGLT2 inhibitors on serum TNF-α levels, and no significant effect was observed (SMD = 0.41; 95% CI: -0.90, 1.73, $p = 0.54$); but there was significant between-study heterogeneity ($I^2 = 98\%, p < 0.001$; Figure 4). Subgroup analyses did not significantly improve the results. After removal of the study conducted by Garvey et al., the $I^2$-value was reduced from 98% to 33%.

---

**Figure 5**
Forest plot of the effects of SGLT2 inhibitors on interleukin-6.

**Figure 6**
Forest plot of the effects of SGLT2 inhibitors on adiponectin.
### FIGURE 7
Forest plot of the effects of SGLT2 inhibitors on leptin.

| Study or Subgroup | Mean (SO) Total | Mean (SO) Total | Std. Mean Difference IV, Random %CI | Std. Mean Difference IV, Random %CI |
|------------------|----------------|----------------|-----------------------------------|-----------------------------------|
| SGLT2 inhibitors vs. placebo | Bailey 2012 -2.7014597 23.315353348 191 -1.54 24.3756152 65 14.2% -0.05 [0.33, 0.23] | Brown 2020 -1477.55 5.289 38 32 477.6 6.314 34 76% -0.14 [0.84, 0.32] | Ishihara 2016 -0.057 0.219 167 -0.021 0.243 87 15.3% -0.14 [0.42, 0.10] | Kashwagi 2015 -0.96 1.658 97 0.72 2.806 54 17.7% -0.73 [0.07, 0.39] | Kashwagi 2015 II -0.13 2.1 62 -0.22 2.1 67 11.6% 0.04 [0.30, 0.36] | Kashwagi 2015 III -0.8 2.187 165 0.23 1.609 75 14.6% -0.29 [0.06, 0.21] | Heterogeneity: Tau² = 0.04; CH² = 12.48; df = 5 (P = 0.03); P = 60% Test for overall effect: Z = 2.09 (P = 0.04) |

### FIGURE 8
Forest plot of the effects of SGLT2 inhibitors on ferritin.

| Study or Subgroup | Mean (SO) Total | Mean (SO) Total | Std. Mean Difference IV, Random %CI | Std. Mean Difference IV, Random %CI |
|------------------|----------------|----------------|-----------------------------------|-----------------------------------|
| SGLT2 inhibitors vs. diabetes medication | Gansey 2018 -1.677 1.18578 99 1.529 14.90522 100 14.3% -0.30 [0.58, 0.02] | Phiavu 2021 -4.5 5.44381 18 -1.7 7.651852 20 5.0% 0.06 [0.36, 0.06] | Sakurai 2020 -0.6 0.570016 31 -1.7 12.56277 18 5.8% 0.10 [0.48, 0.06] | Subtotal (95% CI) 148 138 25.1% -0.17 [0.43, 0.96] | Heterogeneity: Tau² = 0.00; CH² = 2.14; df = 2 (P = 0.34); P = 7% Test for overall effect: Z = 1.36 (P = 0.17) |

### FIGURE 9
Forest plot of the effects of SGLT2 inhibitors on plasminogen activator inhibitor-1.

| Study or Subgroup | Mean (SO) Total | Mean (SO) Total | Std. Mean Difference IV, Random %CI | Std. Mean Difference IV, Random %CI |
|------------------|----------------|----------------|-----------------------------------|-----------------------------------|
| SGLT2 inhibitors vs. placebo | Doherty 2021 -27.8 11.27 1240 -4.3 12.22 1182 18.2% -2.00 [-2.10, -1.90] | Thwale 2021 -59 172.2005 22 -24 95.142 20 16.1% -0.24 [-0.35, 0.03] | Subtotal (95% CI) 1282 1183 34.3% -1.15 [-2.87, 0.57] | Heterogeneity: Tau² = 1.49; CH² = 31.27; df = 1 (P = 0.0001); P = 97% Test for overall effect: Z = 3.71 (P = 0.0001) |

| Study or Subgroup | Mean (SO) Total | Mean (SO) Total | Std. Mean Difference IV, Random %CI | Std. Mean Difference IV, Random %CI |
|------------------|----------------|----------------|-----------------------------------|-----------------------------------|
| SGLT2 inhibitors vs. diabetes medication | Aso 2019 -32 77.0069 33 13.7 82.61796 24 16.5% -0.56 [-1.11, -0.04] | Ito 2017 -72.8 13.1 32 -42.1 13.1 34 15.9% -2.32 [-2.95, -1.68] | Kinouchi 2020 -38.7 13.4 32 -28 21.74198 66 16.8% -1.57 [-2.04, -1.09] | Takashita 2022 -96 113.9337 24 -58.7 13.4 32 16.5% -0.49 [-1.03, 0.05] | Subtotal (95% CI) 121 156 63.7% -1.23 [-2.63, -4.43] | Heterogeneity: Tau² = 0.66; CH² = 26.10; df = 3 (P = 0.0001); P = 99% Test for overall effect: Z = 3.01 (P = 0.003) |

| Total (95% CI) | Subtotal (95% CI) 1383 1359 100.0% -1.21 [-1.91, -0.52] | Heterogeneity: Tau² = 0.69; CH² = 80.39; df = 5 (P = 0.0001); P = 94% Test for overall effect: Z = 3.41 (P = 0.0001) |

| Total (95% CI) | Subtotal (95% CI) 150 138 100.0% -0.38 [-0.61, -0.15] | Heterogeneity: Tau² = 0.00; CH² = 0.43; df = 2 (P = 0.61); P = 0% Test for overall effect: Z = 3.18 (P = 0.001) |
IL-6
A total of six studies investigated the effects of SGLT2 inhibitors on serum IL-6, and meta-analysis results showed no significant effect (SMD = 0.05; 95% CI: −1.12, 1.21, p = 0.94); but there was significant between-study heterogeneity (I² = 97%, p < 0.001; Figure 5). Subgroup analyses did not significantly improve the results, and removal of any study did not significantly improve heterogeneity.

Adiponectin
Seventeen studies investigated the levels of adiponectin following SGLT2 inhibitor intervention. Figure 6 shows the effects of SGLT2 inhibitors on serum adiponectin levels and our analysis demonstrated no significant effect (SMD = −0.04; 95% CI: −0.37, 0.29, p = 0.80; Figure 6). Subgroup analyses revealed a significant adiponectin-improving effect in placebo-controlled studies (SMD: 0.28; 95% CI: 0.15, 0.41, p < 0.001) with no heterogeneity, but it was not significantly reduced in diabetes medications-controlled studies (SMD: −0.51; 95% CI: −1.30, 0.27, p = 0.20). The source of heterogeneity seemed to be from the diabetes medication-controlled subgroup.

Leptin
A total of nine studies investigated the effects of SGLT2 inhibitors on serum leptin levels, and the pooled effect size demonstrated that SGLT2 inhibitors had a significant reduction effect (SMD: −0.20; 95% CI: −0.36, −0.04, p = 0.01) with slight heterogeneity between studies (I² = 45%, p = 0.07; Figure 7). Subgroup analyses revealed a significant leptin-lowering effect in placebo-controlled studies (SMD: −0.22; 95% CI: −0.43, −0.01, p = 0.04), but not in diabetes medications-controlled studies (SMD: −0.17; 95% CI: −0.43, 0.08, p = 0.17).

Ferritin
A total of six studies investigated the effects of SGLT2 inhibitors on serum ferritin levels, and the pooled effect size demonstrated that SGLT2 inhibitors had a significant reduction effect (SMD: −1.21; 95% CI: −1.91, −0.52, p < 0.001) with I² = 94%, suggesting a high level of heterogeneity among the studies (Figure 8). Subgroup analyses revealed a significant ferritin-lowering effect in diabetes medication-controlled studies (SMD: −1.23; 95% CI: −2.03, −0.43, p = 0.003), while only one placebo-controlled study showed no significant reduction (SMD: −1.15; 95% CI: −2.87, 0.57, p = 0.19).

PAI-1 and VCAM-1
A total of three studies investigated the effects of SGLT2 inhibitors on serum PAI-1 levels, and the pooled effect size demonstrated that SGLT2 inhibitors had a significant reduction effect (SMD: −0.38; 95% CI: −0.61, −0.15, p = 0.001) with no heterogeneity between studies (I² = 0%, p = 0.81; Figure 9). However, these three RCTs were all diabetes medication-controlled studies. In addition, VCAM-1 was not assessed due to inadequate data availability, as only one study was available (Garvey et al., 2018).

Subgroup analysis depending on treatment duration
The median length of follow-up was 24 weeks, but there was a large variation (6 weeks–104 weeks). Previous studies have found that many metabolic parameter improvements peaked at about week 24 (Yoshida et al., 2019). Thus, we separated the two subgroups into “0–24 weeks” and “longer than 24 weeks”.

Sensitivity analysis and publication bias
In our meta-analysis of the effects of SGLT2 inhibitor therapy on the inflammatory biomarkers, CRP, TNF-α, IL-6, leptin, adiponectin, and ferritin, the results did not change significantly after removal of any study from the pooled research, which indicated that our analysis model was stable. No evidence of publication bias was detected in this meta-analysis, as the funnel plot of standard error by effect size was symmetrical (Supplementary Figure S3).

Discussion
T2D is closely linked to inflammation, primarily as low-grade chronic inflammation (Luc et al., 2019; Rohm et al., 2022). The high risk of CVD in T2D is inextricably associated with the activation of inflammatory markers (Luc et al., 2019; Rohm et al., 2022). For significant cardiovascular and renal benefits, SGLT2 inhibitors are regarded as a promising treatment for type 2 diabetes (Neal et al., 2017; Zannad et al., 2020; Packer et al., 2021; Paolillo et al., 2022). In this systematic review and meta-analysis, we investigated whether the improvement of CVD and renal outcomes of SGLT2 inhibitor treatment was due to inflammation regulation by analyzing 34 RCTs to assess the effect of SGLT2 inhibitors on biomarkers of inflammation. The results indicated that, compared to placebo or active diabetes medications, treatment with SGLT2 inhibitors significantly reduced serum ferritin levels. A reduction in CRP and leptin, and an increase in adiponectin were demonstrated in placebo-
controlled studies. PAI-1 levels were significantly reduced in diabetes therapy-controlled studies. Given the lack of inflammatory biomarkers from chief cardiorenal outcome RCTs, these results indicate that anti-inflammatory activities may partially mediate the pleiotropic benefits of SGLT2 inhibitors.

Circulating CRP, IL-6, and TNF-α are classic proinflammatory cytokines. We identified 14 eligible studies reporting CRP levels as an outcome measure, seven reporting IL-6 levels, and six reporting TNF-α levels. It was previously shown that SGLT2 inhibitors were associated with reduction of CRP, IL-6, and TNF-α, and reduction of serum CRP appeared to be independent of improvement in HbA1c (Bray et al., 2020). However, except for one subgroup analysis that reported reduced CRP compared to placebo, SGLT2 inhibitors failed to lower the levels of these inflammatory cytokines in our analysis. Among the 13 studies, the largest study was well-designed, and serum CRP did not significantly vary between the tofogliflozin group and the conventional group (Katakami et al., 2020), while only two studies demonstrated a marked decrease in CRP. Hao et al. (2022) and Hattori (2018) were all open-label studies with a "high risk of bias" for performance bias. Notably, unlike GLP-1RAs, SGLT2 inhibitors increase the availability of glucose in the urinary tract, increasing the risk of urinary tract infections (Li et al., 2017). Previous studies showed that SGLT2 inhibitors were linked to infections of the genitourinary tract in T2D (Li et al., 2017; Dave et al., 2019). However, because of conflicting findings with prior meta-analyses reports, the association with UTIs is still unclear (Wu et al., 2016; Puckrin et al., 2018). From the classic proinflammatory markers in our results, we caution against attaching too much importance to the risk of infections of the genitourinary tract from SGLT2 inhibitors, compared with their pleiotropic beneficial impacts on favorable cardiorenal metabolic profiles (Dave et al., 2019).

SGLT-2 inhibitors have been widely reported to promote body weight loss and decline of adipose insulin resistance (Yoshida et al., 2019). Experimental studies have shown the beneficial effects of SGLT-2 inhibitors on adipose tissue metabolism and inflammation (Xu et al., 2017; Xu et al., 2019). In addition to shifting energy metabolism towards fat utilization, SGLT-2 inhibitors were demonstrated to attenuate obesity-related chronic inflammation by reducing M1-polarized macrophage accumulation and inducing the anti-inflammatory M2 macrophage phenotype within adipose tissue and liver in diet-induced obese mice (Xu et al., 2017; Xu et al., 2019). Adiponectin and leptin were identified as unique 'secretomes' mediating inter-organ communication between adipose tissue and the cardiovascular system (Everson-Rose et al., 2021; Zhao et al., 2021). Their associations with cardiovascular disorders are paradoxical, however (Zhao et al., 2021). Uregulation of adiponectin has been linked to suppression of chronic inflammation (Hoong and Chua, 2021). In our results, adiponectin levels were significantly increased in placebo-controlled studies, which are in line with the findings of a previous meta-analysis (Wu et al., 2019). Leptin levels were significantly reduced in placebo-controlled studies, and the underlying mechanism may be due to the alleviation of leptin tolerance reported in findings from obese mice and humans (Perakakis et al., 2021). However, an accurate definition of leptin tolerance and the underlying mechanism awaits further investigation. Evidence has also been found that leptin induces the activation of proinflammatory signaling pathways and the increased synthesis of proinflammatory mediators, thereby resulting in vascular inflammation, endothelial dysfunction and atherosclerosis (La Cava, 2017). Taking these considerations into account, our results also suggest that the protective effects of SGLT2 inhibitors may partly be associated with a reduction in leptin levels (Wu et al., 2019).

Intriguingly, we also found that SGLT2 inhibitors significantly reduced serum ferritin and PAI-1 levels. Serum ferritin has been identified as a biomarker of insulin resistance, liver fat accumulation, and greater CVD risk (Ferrannini et al., 2020; Zhou et al., 2021). However, SGLT2 inhibitor-induced decreases in ferritin levels were also linked to increased erythropoietin levels, and erythropoiesis might be related to the inhibition of inflammatory functions (Thiele et al., 2021), as plasma and tissue PAI-1 levels were increased under pathological conditions (Baumer et al., 2021). The development of PAI-1 inhibitors may provide a potential treatment for renal and cardiovascular disease (Ha et al., 2009). The underlying mechanism of ferritin and PAI-1 reduction by SGLT2 inhibitors certainly deserves further research.

In this meta-analysis, we report a systematic assessment of the effects of SGLT2 inhibitors on a set of inflammatory biomarkers using a robust, systematic methodology. However, we acknowledge some inherent limitations. First, while most major RCTs, such as EMPEROR-Reduced and CANVAS-R, confirmed the cardiorenal protective effects of SGLT2 inhibitors, they did not follow-up on inflammatory biomarkers as outcomes (Packer et al., 2021). Although we conducted a wide-ranging search using four eligible databases, much of the evidence was from smaller trials, of which one-third of RCTs were assessed to have a "high risk of bias", especially performance bias. Second, a limiting factor of the present review is a high degree of heterogeneity in the majority of biomarkers, which may be explained by different dosages, various SGLT2 inhibitors or active diabetes medication controls, as well as methodology of the assays and units of measure. It is also important to note that the majority of studies included in this meta-analysis were not matched for inflammation biomarkers at baseline. Third, the median length of follow-up was 24 weeks, but with wide variation (6 weeks–104 weeks). From the subgroup analysis of CRP, adiponectin, and leptin, it seemed that the impact of SGLT2 inhibitors was related to timeframe. However, the number of RCTs for conducting subgroup analysis was limited.
Longer intervention RCTs are needed to assess the impact of timeframe on these inflammatory biomarkers. Lastly, the data from clinical studies showed that biomarkers of oxidative stress, closely associated with inflammation, were also higher in individuals with diabetes or diabetic complications (Khaloo et al., 2020; Bokhary et al., 2021). However, RCTs on the effect of SGLT2 inhibitors on oxidative stress are still rare, and this is an important area for future research.

Conclusion

In conclusion, this systematic review demonstrated that some circulating inflammatory related biomarkers were significantly altered by SGLT2 inhibitors, a finding that is important in understanding the cardiovascular and renal protective properties of SGLT2 inhibitors. Despite the lack of direct evidence from larger cardiorenal outcome trials on inflammatory biomarkers, there are reasons to believe that this meta-analysis offers different perspectives that will be of use in the clinical application of SGLT2 inhibitors. This meta-analysis also provides a promising future for the ongoing development of similar drugs and related anti-inflammatory agents in metabolic disorders.

Author contributions

Formal analysis and writing--review and editing, DW, JL, and XX; supervision, LnZ, SL, LyZ, QZ, MI, and XX; funding acquisition, XX, JL, and QZ. All authors have read and agreed to the published version of the manuscript.

References

Ahsnbari, A., and Idris, I. (2022). Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? - targeting hyperinflammation. Curr. Med. Res. Opin. 38 (3), 357–364. doi:10.1111/1365-2846.14395

Alshnbari, A., and Idris, I. (2022). Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibitor upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial. Diabetes Obes. Metab. 24 (5), 816–826. doi:10.1111/dob.14639

Aso, Y., Kato, K., Sakurai, S., Kishi, H., Shimizu, M., Jojima, T., et al. (2019). Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. Int. J. Clin. Pract. 73 (5), e13335. doi:10.1111/ijcp.13335

Baumeier, C., Escher, F., Aleshcheva, G., Pietsh, H., and Schultheiss, H. P. (2021). Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 macrophage polarization in inflammatory cardiomyopathy. Basic Res. Cardiol. 116 (1), 1. doi:10.1007/s00395-020-00840-w

Bilen, A., Calik, I., Yayla, M., Dincer, B., Tavaci, T., Cinar, I., et al. (2021). Does daily fasting shielding kidney on hyperglycemia-related inflammatory cytokine via TNF-α, NLRPA1, TGF-β1 and VCAM-1 mRNA expression. Int. J. Biol. Macromol. 190, 911–918. doi:10.1016/j.ijbiomac.2021.08.216

Bokhary, K., Aljaser, F., Abudawood, M., Tabassum, H., Bakhsh, A., Alhammad, S., et al. (2021). Role of oxidative stress and severity of diabetic retinopathy in type 1 and type 2 diabetes. Ophthal. Res. 64 (4), 613–621. doi:10.1080/03007995.2021.190832

Braunwald, E. (2019). Diabetes, heart failure, and renal dysfunction: The vicious circles. Prog. Cardiovasc. Dis. 62 (4), 298–302. doi:10.1016/j.pcad.2019.07.003

Bray, J. H., Foster-Davies, H., Salem, A., Hoole, A. L., O’Hara, D. R., Halcox, J. P. J., et al. (2021). Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials. Diabetes Obes. Metab. 23 (8), 1806–1822. doi:10.1111/dob.13499

Funding

This work was supported by the grants from the National Natural Science Foundation of China (No. 82170854, 81900723, 81870579, 81870545, 81570715, and 8170736), Beijing Natural Science Foundation (7202163), and Fundamental Research Funds for the Central Universities (3332021094).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.1045235/full#supplementary-material
biomarkers of inflammation and oxidative stress. *Diabetes Res. Clin. Pract.* 168, 108368. doi:10.1016/j.diabres.2020.108368

Brown, A. J. M., Gandy, S., McCormick, R., Houston, J. G., Struthers, A. D., and Lang, C. C. (2020). A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type 2 diabetes: The DAPA-LVH trial. *Eur. Heart J.* 41 (36), 3421–3432. doi:10.1093/eurheartj/ehaa419

Cahn, A., Raz, I., Leiter, L. A., Mosenzon, O., Murphy, S. A., Goodrich, E. L., et al. (2021). Cardiovascular, renal, and metabolic outcomes of dapagliflozin versus placebo in primary cardiovascular prevention cohort: Analyses from DECLARE-TIMI 58. *Diabetes care* 44 (5), 1159–1167. doi:10.2337/dcds.2020-2492

Dave, C. V., Schneeweiss, S., Kim, D., Fralick, M., Tong, A., and Paterno, E. (2019). Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: A population-based cohort study. *Ann. Intern. Med.* 171 (4), 248–256. doi:10.7326/m18-3136.

Dekkers, C. C. J., Petrykiv, S., Laverman, G. D., Cherney, D. Z., Gansvoort, R. T., and Heerspink, H. J. L. (2018). Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. *Diabetes Metab. Obstet.* 20 (8), 1988–1993. doi:10.1111/dmno.13301

Docherty, K. F., Welsh, P., Verma, S., De Boer, R. A., O'Meara, E., Bengtsson, O., et al. (2022). Iron deficiency in heart failure and effect of dapagliflozin: Findings from DAPA-HF. *Circulation* 146 (13), 980–994. doi:10.1161/circulationaha.122.060511

Eckloff, M. K., Olsen, F. J., Fremdolt-Moller, M., Diaz, L. J., Faber, J., Jensen, M. E., et al. (2021). Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria – a double blind randomized placebo-controlled crossover trial. *J. Diabetes Complicat.* 34 (7), 107590. doi:10.1016/j.jdiacomp.2020.107590.

Ejiri, K., Miyoshi, T., Kihara, H., Hata, Y., Naganoto, T., Takaisi, A., et al. (2022). Effects of lusoglin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure. *Sci. Rep.* 12 (1), 15449. doi:10.1038/s41598-022-19376-6.

Eversion-Rose, S. A., Barinas-Mitchell, E. J., Kloudary, S. R., Huang, H. H., Wang, Q., Janssen, I., et al. (2021). Adipokines and subclinical cardiovascular disease in heart failure patients with type 2 diabetes mellitus: A combined phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. *Cardiovasc. Diabetol.* 15, 65. doi:10.1186/s12933-016-0144-y.

Kashiwagi, A., Akiyama, N., Shiga, T., Karata, K., Utsunomiya, K., et al. (2021). Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: Results of the randomized, placebo-controlled, double-blind, phase III EMIT study. *Diabetol. Int.* 6 (2), 125–138. doi:10.1007/s13340-014-0184-9

Kashiwagi, A., Karata, K., Takinami, Y., Yoshida, S., Utsunomiya, T., and Nagase, I. (2015). Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: The BRIGHTEN study: Brighten: Double-blind randomized study of ipragliflozin to show its efficacy as monotherapy in T2DM patients. *Diabetol. Int.* 6 (1), 8–18. doi:10.1007/s13340-014-0164-0.

Kashiwagi, A., Shiga, T., Akiyama, N., Karata, K., Utsunomiya, S., and Yoshida, S., et al. (2015). Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: A randomized, double-blind, placebo-controlled study (the SPOTLIGHT study). *Diabetol. Int.* 6 (2), 104–116. doi:10.1007/s13340-014-0182-y.

Katakami, N., Mitu, T., Yoshii, H., Shiraiwa, T., Yasuda, T., Okada, Y., et al. (2020). Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes. A prospective, randomized, open-label, parallel-group comparative study. *Cardiovasc. Diabetol.* 19 (1), 110. doi:10.1186/s12933-020-01079-4.

Khalov, P., Qahrameni, R., Rabizadeh, S., Omidi, M., Rajab, A., and Hashi, F., et al. (2020). Nitric oxide and TNF-α are correlates of diabetic retinopathy independent of hs-CRP and HBA1c. *Endocrine* 69 (3), 536–541. doi:10.1007/s13340-020-02353-x.

Kinosita, T., Shimoda, M., Nakashima, K., Fushimi, Y., Hira, R., and Tanabe, A., et al. (2020). Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study. *J. Diabetes Invest.* 11 (6), 1612–1622. doi:10.1111/jdi.13279.

Koshizuka, M., Ishikawa, K., Ishibashi, R., Maewara, Y., Sakamoto, K., Uchida, D., et al. (2019). Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (prime-V study). *Diabetol. Metab. Ther.* 21 (8), 1990–1995. doi:10.1136/dmt-2017-013750.

La Cava, A. (2017). Leptin in inflammation and autoimmunity. *Cytokine* 98, 51–58. doi:10.1016/j.cyto.2016.10.011.

Latra-Rasku, A., Honka, M. J., Kullberg, J., Mononen, N., Lehtimaki, T., Salo, J., et al. (2019). The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: A randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients. *Diabetes care* 42 (5), 931–937. doi:10.2337/dc18-1569.

Lekvø, T., Michelsen, A. E., Aukrust, P., Tønnessen, T., Bollerslev, J., and Ueland, T. (2017). Leptin and adiponectin as predictors of cardiovascular risk after gestational diabetes mellitus. *Cardiovasc. Diabetol.* 16 (1), 5. doi:10.1186/s12933-016-0492-4.

Li, D., Wang, T., Shen, S., Fang, Z., Dong, Y., and Tang, H. (2017). Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. *Diabetol. Metab. Ther.* 19 (5), 348–355. doi:10.1186/s12933-018-0628-5.

Luc, K., Schramm-Luc, A., Guzik, T. J., and Mikolajczyk, T. P. (2019). Oxidative stress and inflammatory markers in prediabetes and diabetes. *J. Physiol. Pharmacol.* 70 (6), 621–648. doi:10.1007/s12266-019-0548-5.

Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., and Ernou, N., et al. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N. Engl. J. Med.* 377 (7), 644–657. doi:10.1056/NEJMoai1611925.

Oldgren, J., Laurila, S., Akerblom, A., Onofrio, N., Maiello, C., Trotta, M. C., and Sardu, C., et al. (2022). Sodium-glucose cotransporter-2 (SGLT2) expression in diabetes and non-diabetic failing human cardiomyocytes. *Pharmacol. Res.* 184, 106448. doi:10.1016/j.phrs.2022.106448.

Omar, M., Jensen, J., Kristorup, C., Hjelmd, K., Videbæk, L., Tuxen, C., et al. (2022). The effect of empagliflozin on growth differentiation factor 15 in patients with type 2 diabetes. A randomized, double-blind, phase 4, placebo-controlled trial. *Diabetes care* 43 (2), 298–305. doi:10.2337/dci19-0641.
with heart failure: A randomized controlled trial (empire HF biomarker). 
*Cardiovasc. Diabetol.* 21 (1), 34. doi:10.1186/s12933-022-01463-2

Packer, M., Anker, S. D., Butler, J., Filippatos, G., Ferrerria, J. P., Pocock, S. J., et al. (2021). Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: The EMPORER-reduced trial. *Circulation* 143 (4), 326–336. doi:10.1161/circulationaha.120.051783

Paolillo, P., Bergamaschi, L., Santulli, G., Gallinoro, E., Cesaro, A., Gragagno, F., et al. (2022). Infaert size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2 inhibitors: A multicenter international registry. *Cardiovasc. Diabetol.* 21 (1), 77. doi:10.1186/s12933-021-01506-8

Perakakis, N., Farr, O. M., and Mantzoros, C. S. (2021). Leptin in leanness and obesity: JACC-state-of-the-art review. *J. Am. Coll. Cardiol.* 77 (6), 745–760. doi:10.1016/j.jacc.2020.11.069

Phrommintikul, A., Wongcharoen, W., Kumfu, S., Jaiwongkam, T., Gunaparn, S., Chuttipakorn, S., et al. (2019). Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease. A randomized study. *Br. J. Clin. Pharmacol.* 85 (6), 1337–1347. doi:10.1111/bcp.13903

Phraeuktsai, S., Panypornpanish, K., Euaithrongchit, J., Learapun, A., Phrommintikul, A., Buranapin, S., et al. (2021). The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease. *J. Gastroenterol. Hepatol.* 36 (10), 2952–2959. doi:10.1111/jgh.15380

Puckrin, R., Saltiel, M. P., Reynier, P., Arozayad, L., Yu, O. H. Y., and Filion, K. B. (2018). SGLT-2 inhibitors and the risk of infections: A systematic review and analysis of randomized controlled trials. *Acta Diabetol.* 55 (5), 503–514. doi:10.1007/s00592-018-1116-0

Qu, D., Liu, J., Lau, C. W., and Huang, Y. (2014). IL-6 in diabetes and cardiovascular complications. *Br. J. Pharmacol.* 171 (15), 3595–3603. doi:10.1111/bph.12713

Rohm, T. V., Meier, D. T., Olefsky, J. M., and Donath, M. Y. (2022). Inflammatory role of SGLT2 inhibitors as part of their anti-inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2 inhibitors: Data from a randomized, placebo-controlled study. *Diabetes Obes. Metab.* 23 (12), 2814–2818. doi:10.1111/dom.14517

Winiarska, A., Knyasak, M., Nabrdalik, K., Gumprecht, J., and Stemp às t, T. (2021). Inflammation and oxidative stress in diabetic kidney disease: The targets for SGLT2 inhibitors and OGL-1 receptor agonists. *Int. J. Mol. Sci.* 22 (19), 10822. doi:10.3390/ijms221910822

Wu, J. H., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., et al. (2016). Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis. *Lancet. Diabetes Endocrinol.* 4 (5), 411–419. doi:10.1016/s2213-8587(16)00052-8

Wu, P., Wen, W., Li, J., Xu, J., Zhao, M., Chen, H., et al. (2019). Systematic review and meta-analysis of randomized controlled trials on the effect of SGLT2 inhibitor on blood leptin and adiponectin level in patients with type 2 diabetes. *Horm. Metab. Res.* 51(8):473–494. doi:10.1155/S0899500719680552

Xu, L., Nagata, N., Chen, G., Nagashimada, M., Zhuge, F., Ni, Y., et al. (2019). Empagliflozin reverses obesity and insulin resistance through fat burning and alternative macrophage polarization in diet-induced obese mice. *BMJ Open Diabetes Res. Care* 7 (1), e000783. doi:10.1136/bmjdrc-2019-000783

Xu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., et al. (2017). SGLT2 inhibition by empagliflozin promotes fat utilization and burning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. *Elife* 2021.550011

Zhao, S., Kusminski, C. M., and Scherer, P. E. (2021). Adiponectin, leptin and cardiovascular disorders. *Nat. Rev. Endocrinol.* 17, 137–149. doi:10.1038/s41574-016-00078-1

Zhou, B., Liu, S., and Yuan, G. (2021). Combined associations of serum ferritin and hs-CRP with type 2 diabetes mellitus and its complications. *Nat. Rev. Endocrinol.* 14 (2), 88–98. doi:10.1038/s41574-017-151

Zhoud, B., Liu, S., and Yuan, G. (2021). Combined associations of serum ferritin and body size phenotypes with cardiovascular risk profiles: A Chinese population-based study. *Front. Public Health 9*, 550011. doi:10.3389/fpubh.2021.550011